Prostacyclin Analogue Program

About Eicos Sciences

Eicos Sciences is a private, preclinical-stage biotech leveraging the established biology of prostacyclins to develop novel therapies for severe, underserved conditions. The company's platform centers on the anti-inflammatory, antiplatelet, and vasodilatory properties of PGI2 analogues, aiming to address high-need areas like frostbite and systemic sclerosis. While the company appears to be in an early operational phase with a basic website, its scientific premise targets clear unmet medical needs in niche vascular and inflammatory disorders.

About Eicos Sciences

Eicos Sciences is a private, preclinical-stage biotech leveraging the established biology of prostacyclins to develop novel therapies for severe, underserved conditions. The company's platform centers on the anti-inflammatory, antiplatelet, and vasodilatory properties of PGI2 analogues, aiming to address high-need areas like frostbite and systemic sclerosis. While the company appears to be in an early operational phase with a basic website, its scientific premise targets clear unmet medical needs in niche vascular and inflammatory disorders.

About Eicos Sciences

Eicos Sciences is a private, preclinical-stage biotech leveraging the established biology of prostacyclins to develop novel therapies for severe, underserved conditions. The company's platform centers on the anti-inflammatory, antiplatelet, and vasodilatory properties of PGI2 analogues, aiming to address high-need areas like frostbite and systemic sclerosis. While the company appears to be in an early operational phase with a basic website, its scientific premise targets clear unmet medical needs in niche vascular and inflammatory disorders.

Therapeutic Areas